Onkologie, Hämatologie - Daten und Informationen
SitemapSitemap  


Literatur zu Kapitel 4.11: Antikörper

Autor/en: A. Kerstan, E.-B. Bröcker
Letzte Änderung: 01.12.2006
  • Abken H et al.
    Tuning tumor-specific T-cell activation: a matter of costimulation?
    Trends Immunol 2002;23:240-245.


  • Becker JC et al.
    T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy.
    J Exp Med 1996a;183:2361-2366.


  • Becker JC et al.
    Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins.
    Proc Natl Acad Sci USA 1996b;93:2702-2707.


  • Boon T et al.
    Tumor antigens recognized by T lymphocytes.
    Annu Rev Immunol 1994;12:337-65.


  • Carter P.
    Improving the efficacy of antibodybased cancer therapies.
    Nat Rev Cancer 2001;1:118-129.


  • Chapman PB et al.
    Mapping effector functions of a monoclonal antibody to GD3 by characterization of a mouse-human chimeric antibody.
    Cancer Immunol Immunother 1994;39:198-204.


  • Cheresh DA et al.
    Localization of the gangliosides GD2 and GD3 in adhesion plaques and on the surface of human melanoma cells.
    Proc Natl Acad Sci USA 1984;81:5767-5771.


  • Clark M.
    Antibody humanization: a case of the ‘Emperor's new clothes'?
    Immunol Today 2000;21:397-402.


  • Cochlovius B et al.
    Human melanoma therapy in the SCID mouse: in vivo targeting and reactivation of melanoma-specific cytotoxic T cells by bi-specific antibody fragments.
    Int J Cancer 1999;81:486-493.


  • Colucci F, Caligiuri MA, Di Santo JP.
    What does it take to make a natural killer?
    Nat Rev Immunol 2003;3:413-425.


  • Dippold WG et al.
    Immunohistochemical localization of ganglioside GD3 in human malignant melanoma, epithelial tumors, and normal tissues.
    Cancer Res 1985;45:3699-3705.


  • Dippold WG et al.
    Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies.
    Proc Natl Acad Sci USA 1980;77:6114-6118.


  • Dranoff G.
    GM-CSF-secreting melanoma vaccines.
    Oncogene 2003;22:3188-3192.


  • Egen, JG, Kuhns MS, Allison JP.
    CTLA-4: new insights into its biological function and use in tumor immunotherapy.
    Nat Immunol 2002;3:611-618.


  • Gillies SD et al.
    Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells.
    Proc Natl Acad Sci USA 1992;89:1428-1432.


  • Green MC, Murray JL, Hortobagyi GN.
    Monoclonal antibody therapy for solid tumors.
    Cancer Treat Rev 2000;26:269-286.


  • Grosse-Hovest L et al.
    Tumor-growth inhibition with bispecific antibody fragments in a syngeneic mouse melanoma model: the role of targeted T-cell co-stimulation via CD28.
    Int J Cancer 1999;80:138-144.


  • Hanai N, Nakamura K, Shitara K.
    Recombinant antibodies against ganglioside expressed on tumor cells.
    Cancer Chemother Pharmacol 2000;46 Suppl:13-17.


  • Hodi FS et al.
    Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.
    Proc Natl Acad Sci USA 2003;100:4712-4717.


  • Houghton AN, Gold JS, Blachere NE.
    Immunity against cancer: lessons learned from melanoma.
    Curr Opin Immunol 2001;13:134-140.


  • Hurwitz AA, Kwon ED, van Elsas A.
    Costimulatory wars: the tumor menace.
    Curr Opin Immunol 2000;12:589-596.


  • Kaminski MJ et al.
    The role of homophilic binding in anti-tumor antibody R24 recognition of molecular surfaces. Demonstration of an intermolecular beta-sheet interaction between vh domains.
    J Biol Chem 1999;274:5597-5604.


  • King DM et al.
    Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients.
    J Clin Oncol 2004;22:4463-4473.


  • Kirkwood JM et al.
    Analysis of therapeutic and immunologic effects of R(24) anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma.
    Cancer 2000;88:2693-2702.


  • Koni PA et al.
    Distinct roles in lymphoid organogenesis for lymphotoxins alpha and beta revealed in lymphotoxin beta-deficient mice.
    Immunity 1997;6:491-500.


  • Nakamura K et al.
    Construction of humanized anti-ganglioside monoclonal antibodies with potent immune effector functions.
    Cancer Immunol Immunother 2001;50:275-284.


  • Nasi ML et al.
    Anti-melanoma effects of R4, a monoclonal antibody against GD3 ganglioside.
    Melanoma Res 1997;27 Suppl 2:155-162.


  • Ohta S et al.
    Antitumor effects of a novel monoclonal antibody with high binding affinity to ganglioside GD3.
    Cancer Immunol Immunother 1993;36:260-266.


  • Ortaldo JR et al.
    Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies.
    J Immunol 1987;138:3566-3572.


  • Phan GQ et al.
    Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.
    Proc Natl Acad Sci USA 2003;100:8372-8377.


  • Pukel CS et al.
    GD 3, a prominent ganglioside of human melanoma. Detection and characterisation by mouse monoclonal antibody.
    J Exp Med 1982:155;1133-1147.


  • Ramirez-Montagut T et al.
    Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity.
    Oncogene 2003;22:3180-3187.


  • Reisfeld RA et al.
    Involvement of B lymphocytes in the growth inhibition of human pulmonary melanoma metastases in athymic nu/nu mice by an antibody-lymphotoxin fusion protein.
    Cancer Res 1996;56:1707-1712.


  • Rettig WJ, Old LJ.
    Immunogenetics of human cell surface differentiation.
    Annu Rev Immunol 1989;7:481-511.


  • Riedle S, Rosel M, Zoller M.
    In vivo activation and expansion of T cells by a bi-specific antibody abolishes metastasis formation of human melanoma cells in SCID mice.
    Int J Cancer 1998;75:908-918.


  • Rohrbach P et al.
    Therapeutic antibodies and antibody fusion proteins.
    Biotechnol. Genet Eng Rev 2003;20:137-163.


  • Rosenberg SA.
    Progress in human tumour immunology and immunotherapy.
    Nature 2001;411:380-384.


  • Sanz L, Blanco B, Alvarez-Vallina L.
    Antibodies and gene therapy: teaching old ‘magic bullets' new tricks.
    Trends Immunol 2004;25:85-91.


  • Schrama D et al.
    Targeting of lymphotoxinalpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue.
    Immunity 2001;14:111-121.


  • Scott AM et al.
    Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trial.
    J Clin Oncol 2001;19:3976-3987.


  • Shitara K et al.
    A mouse/human chimeric anti-(ganglioside GD3) antibody with enhanced antitumor activities.
    Cancer Immunol Immunother 1993;36:373-380.


  • Soiffer R et al.
    Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colonystimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.
    J Clin Oncol 2003;21:3343-3350.


  • Straten PT et al.
    Activation of preexisting T cell clones by targeted interleukin 2 therapy.
    Proc Natl Acad Sci USA 1998;95:8785-8790.


  • Sutmuller RP et al.
    Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses.
    J Exp Med 2001;194:823-832.


  • Tivol EA et al.
    Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.
    Immunity 1995;3:541-547.


  • van Elsas A, Hurwitz AA, Allison JP.
    Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
    J Exp Med 1999;190:355-366.


  • van Elsas A et al.
    Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy.
    J Exp Med 2001;194:481-489.


  • Waterhouse P et al.
    Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4.
    Science 1995;270:985-988.


Bei ONKODIN publiziert in Kooperation mit "Deutscher Ärzte-Verlag"; Publikation als Buch: Deutscher Ärzte-Verlag  Deutscher Ärzte-Verlag
[Mehr]
Aktuelle Berichte vom 58th
ASH Annual Meeting 2016,
San Diego, Kalifornien, USA [Mehr]
2016 ASCO Annual Meeting - aktuelle Berichte. Dieser Service wird gefördert durch:
mehr 
[Mehr]